Related Experiment Video
Updated: Aug 29, 2026

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
[EGF receptors in urological cancer. Molecular basis and therapeutic involvements]
Bernard Paule1, Nathalie Brion
1Service d'Urologie, Hôpital Henri-Mondor, 54, avenue du Maréchal-de-Lattre-de-Tassigny, 94010 Créteil.
Abstract:
Many epithelial cancers have been found to overexpress the receptor to epidermal growth factor (EGFR) including head and neck, breast, colon, lung, prostate, kidney, ovary, brain, pancreas and bladder cancer. Because of the association of EGFR overexpression with overall poor prognosis in patients with cancer, a number of strategies to block or downregulate EGFR have been developed to inhibit tumor proliferation and improve clinical outcome. These include monoclonal antibodies directed against the EGFR such as IMC-C225 which specifically targets EGFR and ZD 1839 (Iressa) capable of inhibiting EGFR tyrosine-kinase in vitro. This report will focus on antibodies that target EGFR in renal cell carcinoma, prostate cancer and bladder cancer.
More Related Videos
04:45Integration of Electroporation in Urological Practice: Design and Evaluation of a New Transurethral Electrode
Published on: March 20, 2026
09:28Patient-derived Orthotopic Xenograft Models for Human Urothelial Cell Carcinoma and Colorectal Cancer Tumor Growth and Spontaneous Metastasis
Published on: May 12, 2019
Related Concept Videos
Mitogens and the Cell Cycle
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Regulation of Angiogenesis and Blood Supply